503 Backend fetch failed

Error 503 Backend fetch failed

Backend fetch failed

Guru Meditation:

XID: 676855946


Varnish cache server

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
503 Backend fetch failed

Error 503 Backend fetch failed

Backend fetch failed

Guru Meditation:

XID: 676855950


Varnish cache server

Emergent BioSolutions : Argus Research Downgrades Emergent Biosolutions to Hold From Buy

05/05/2021 | 09:20am EDT


ę MT Newswires 2021
All news about EMERGENT BIOSOLUTIONS INC.
10/18EMERGENT BIOSOLUTIONS : Announces Initiation of Pivotal Phase 3 Study Evaluating the Safet..
AQ
10/18EMERGENT BIOSOLUTIONS : to Release Third Quarter 2021 Financial Results and Conduct a Conf..
AQ
10/15EMERGENT BIOSOLUTIONS : Emergency BioSolutions Doses First Patient in Phase 3 Trial of Vac..
MT
10/15EMERGENT BIOSOLUTIONS : Announces Initiation of Pivotal Phase 3 Study Evaluating the Safet..
AQ
10/15Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safe..
CI
10/01EMERGENT BIOSOLUTIONS : Unit Gets Additional AV7909 Dose Order From BARDA -- Shares Jump
MT
10/01EMERGENT BIOSOLUTIONS : Material Definitive Agreement (Form 8-K)
PU
10/01EMERGENT BIOSOLUTIONS INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/21SHUMAN, GLENN & STECKER : Investigates Emergent BioSolutions, Inc.
BU
09/14Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19
AQ
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 797 M - -
Net income 2021 356 M - -
Net Debt 2021 152 M - -
P/E ratio 2021 7,90x
Yield 2021 -
Capitalization 2 731 M 2 731 M -
EV / Sales 2021 1,60x
EV / Sales 2022 1,54x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 50,86 $
Average target price 83,33 $
Spread / Average Target 63,8%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-44.36%2 731
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158